Paul Harty is the Chief Solutions Officer of Sevenstep RPO, a Motion Recruitment Partners company. Sevenstep is a leading provider of large-scale hiring solutions, using a unique team-based model of RPO services delivery. Paul is responsible for the companies strategic solutions suite of services and leads the innovation team that drives new technology approaches to solve clients most urgent talent recruiting and talent management strategies. Prior to joining Sevenstep, Paul spent 15 years building and managing a successful technology recruiting and placement businesses. He lives in the Boston area with his wife and children. His son, Matthew, died of Pyruvate Dehydrogenase Deficiency at the age of 8. While searching for answers for his son’s disabilities and managing through a long diagnosis process, Paul discovered MitoAction as a strong support system and a way to gain knowledge about Mito. Paul became an active member to guarantee that other caregivers or patients who are faced with Mito have access to continued support and knowledge that is so necessary when dealing with rare disease.
Gordon Russell is a native Bostonian. He grew up in Weston, MA and attended Hobart College and the Boston University School of Fine Arts. He lost his wife, Sandra, to MELAS in 2008. Gordon is the owner of In The Pink Stores Inc., which he and Sandra founded in 1996. In The Pink operates six retail clothing stores in Massachusetts. Gordon has two children, Buck and Jonathan, and resides in Wellesley, MA. During Sandra’s struggle with MELAS, Gordon and his boys experienced firsthand the support and guidance provided by MitoAction and came to fully understand how critical a role the organization plays. Gordon is serving on the MitoAction board to support MitoAction’s evolution and to ensure MitoAction will always be positioned to provide vital support to individuals and families affected by mitochondrial disease.
Thomas R. Keery, II is the General Partner of the Keery Family Limited Partnership, a real estate partnership with commercial and residential properties in Massachusetts. Prior to entering the real estate business, Tom was president of Frost Motors Inc., a Newton, MA dealership holding company. In operation since 1934, Tom joined the family business upon his graduation from Ithaca College in 1975 with a degree in Communications. Since 1985, Tom had been the Dealer Principal, and has successfully grown the business, acquiring and selling several dealerships. In 2002, he was named the Massachusetts recipient of Time Magazine’s Quality Dealer Award, which is given annually to automobile dealers in recognition of their leadership in community and Industry affairs.
Tom is a member and past president of the Rotary Club of Newton, a member of St. Peter’s Church in Weston, a past director and officer of the YMCA, and a member and past director of the Newton Needham Chamber of Commerce. He is also a current member of the Board of Directors of the Village Bank in Newton. Tom’s sister Sandra passed away in 2008 due to MELAS.
Born in Newton in 1953, Tom resides in Weston with his wife, Laura, where they raised their four children. He enjoys golf and cycling.
Marie grew up in Weston, MA and began her career in finance and accounting at the Seaport Hotel in Boston. She recently made a career move to the Mobile Advertising industry and is currently working as the Accounting Manager at Adelphic Mobile, Inc. She was inspired to volunteer for MitoAction when a family friend, Sandra Russell, needed support during her battle with MELAS. Since her first walk with Sandra’s Stars, Marie has been an active volunteer at Boston area events, including managing the betting tables during the Sandra K. Russell Derby Day Benefit for Mito. As a young professional, it is her hope to be able to engage others and teach them about the importance of MitoAction to the mitochondrial disease community.
Philip Borden is Managing Partner for Galen Partners. Prior to Galen, Philip was with Riverside Partners, a private equity firm based in Boston, where he was responsible for the firm’s investments in healthcare companies. Philip attended Duke University and earned an MBA from Harvard Business School, where he was a Baker Scholar.
Philip has lived in the Greater Boston area for more than a decade and currently resides in Cambridge with his wife, Catherine. Catherine suffers from mitochondrial disease, and Philip became involved with MitoAction following her diagnosis. Catherine and Philip have a vizsla named Rummy, who brings them lots of joy (but sometimes chews their furniture and shoes).
Jessie is the vice president of corporate marketing and creative services for Bright Horizons, the world’s leading provider of employer-sponsored child care and work/life solutions. She is a former opinion columnist for the Sunday Boston Globe and is the author of “Moving On: How to Make the Transition from College to the Real World.” Prior to working at Bright Horizons, Jessie ran her own writing business, Fein Print. Jessie is the mom of three incredible children, Jonah, Dalia, and Theo. Dalia has the mitochondrial disease MERRF Syndrome.
Saad Dinno, RPh, FIACP, FACA, has given lectures on mitochondrial disease across the country as well as in Australia. His staff works with patients and their providers on insurance coverage issues, compliance, taste, dosage form, counseling on the medications being dispensed, and other relevant Mito information and general questions.
He is a member of the Massachusetts Independent Pharmacy Association, Massachusetts Pharmacist Association, National Community Pharmacist Association, and International Academy of Compounding Pharmacists. He is the past president of the Massachusetts Independent Pharmacy Association and previously served on the Professional Compounding Centers of America (PCCA) Advisory Board.
Saad has received numerous awards, including being named the Margaret Bauman Outstanding Medical Professional for his work serving the autism community.
He was also named Massachusetts Innovative Pharmacist of the Year, PCCA Pharmacist of the Month, and received a Fellowship distinction from the International Academy of Compounding Pharmacists. Additionally, Saad serves on Emerson Hospital’s Care Transition Collaborative Committee, the Eliot Community Human Rights Committee, Cardinal Distribution East Advisory Board and the MitoAction Marcel Way Fund Committee. He received his Bachelor of Science degree in pharmacy from the Massachusetts College of Pharmacy and Health Sciences.
Andrew A. Nierenberg, M.D. graduated from the Albert Einstein College of Medicine of Yeshiva University, Bronx, NY, did his residency in psychiatry at New York University/Bellevue Hospital, and studied clinical epidemiology at Yale University as a Robert Wood Johnson Clinical Scholar. Dr. Nierenberg then joined the faculty at Harvard Medical School, first at McLean Hospital in Belmont, Massachusetts and then at Massachusetts General Hospital (MGH), where he holds his current positions.
He is also Honorary Professor in the School of Medicine, Faculty of Health at Deakin University, Geelong Australia and the Honorary Skou Professor of Psychiatry at Aarhus University in Denmark.
Dr. Nierenberg has published over 485 papers and has been listed in The Best Doctors in America for the treatment of mood and anxiety disorders in every edition since 1994. In 2000, he was awarded the Gerald L. Klerman Young Investigator Award and in 2014 the Gerald L. Klerman Senior Investigator Award by the Depression Bipolar Support Alliance. In 2013, Dr. Nierenberg was awarded the prestigious Brain and Behavior Research Foundation Colvin Prize for outstanding achievement in mood disorders research. In 2014, he was awarded the Mentorship Award for Exceptional Mentorship in the Research Arena at MGH.
In 2014, 2015, 2016, and 2017, he was listed among the World’s Most Influential Scientific Minds by Clarivate Analytics in recognition of ranking among the top 1% of researchers for most cited papers in psychiatry worldwide with over 25,000 citations and an h-factor of 79.
Dr. Nierenberg’s primary interest is innovative treatments for bipolar disorder. He lectures extensively, both nationally and internationally, teaches, supervises, maintains an active clinical practice, consults to industry, and conducts clinical trials funded by federal, foundation, industry, and philanthropic sources.
Dr. Nierenberg is the deputy editor of Depression and Anxiety and editor of Psychiatric Annals. He is a member of the editorial boards of over 15 journals including the Journal of Clinical Psychiatry, Journal of Clinical Psychopharmacology, Journal of Affective Disorders, Australian New Zealand Journal of Psychiatry, and Bipolar Disorders and serves as a peer reviewer for over 35 psychiatric journals.